The CD33 antigen exhibits high expression levels in AML blasts; however, normal myeloid progenitors also express CD33 antigen, limiting its potential as an immunotherapeutic target for AML (Ehninger et al., 2014). This evidence concerns the gene CD33 and acute myeloid leukemia.